Open AccessIn Reply
Author(s) -
Ferreri Andrés J.M.,
Gospodarowicz Mary,
Zucca Emanuele,
Christie David
Publication year - 2014
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2014-0232
Subject(s) - medicine , anthracycline , radiation therapy , lymphoma , oncology , chemotherapy , diffuse large b cell lymphoma , intensive care medicine , cancer , breast cancer
The authors thank Hoppe et al. for their interest in the study of patients with limited‐stage diffuse large B‐cell lymphoma of the bone (PB‐DLBCL). There is agreement that patients with PB‐DLBCL should be managed with anthracycline‐based chemotherapy and, if local practice includes it, radiotherapy and that treatment decisions should be based on patient characteristics, lymphoma extension, anatomical site, and conventional risk factors.